Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma

BACKGROUND. Relapsed or refractory mantle cell lymphoma (MCL) has a poor prognosis. The best outcome is achieved in patients who have a partial or complete response to salvage treatment and proceed to allogeneic stem cell transplant. PATIENTS AND METHODS. Twenty‐one patients were given a combination...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Lee, Hun Ju, Romaguera, Jorge E., Feng, Lei, Desai, Aakash P., Zhang, Liang, Fanale, Michelle, Samaniego, Felipe, Hagemeister, Fredrick B., Fayad, Luis E., Rodriguez, Maria A., Medeiros, Jeffrey L., Hartig, Kimberly, Nomie, Krystle, Ahmed, Makhdum, Badillo, Maria, Ye, Haige, Oki, Yasuhiro, Lin, Pei, Nastoupil, Loretta, Westin, Jason, Wang, Michael
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AlphaMed Press 2017
Konular:
Hematologic Malignancies
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5423503/
https://ncbi.nlm.nih.gov/pubmed/28408615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0328
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller